Literature DB >> 21180268

Retinopathy of prematurity--epidemics, incidence, prevalence, blindness.

K Gergely1, A Gerinec.   

Abstract

Currently, there are enough financial resources in industrial most developed countries to provide quality health care to the risk population of premature children. Neonatological units are equipped with state-of-the-art technological background, and highly qualified personnel are employed at the units. This as well allows providing optimum care of extremely immature newborns. ROP prevalence in these countries reaches approximately 5-8%. Today, a boom of surviving premature newborns can be seen in countries with medium-developed economy. Nevertheless, limited financing resources do not allow for standard high-level care. In such countries, the prevalence reaches up to 30%. In this respect, the "third ROP epidemic" is mentioned. Birth weight and gestational age parameters achieve significantly lower values in ROP-infants than in those not affected by the disease. Higher number of surviving immature newborns correlates with an increased risk of advanced ROP stages occurrence, while the frequency and degree of the disease are of inverse nature to the gestational age and birth weight (Tab. 1, Ref. 39).

Entities:  

Mesh:

Year:  2010        PMID: 21180268

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  11 in total

1.  Refractive and Visual Outcome after Laser-Treated Retinopathy of Prematurity in Western Romania.

Authors:  Florina Stoica; Corina Ladariu; Marie-Jeanne Koos; Alina Stanciu; Gabriela Olariu; Nicoleta Andreescu; Maria Puiu
Journal:  Maedica (Buchar)       Date:  2016-06

2.  Correlation of interactions between NOS3 polymorphisms and oxygen therapy with retinopathy of prematurity susceptibility.

Authors:  Chunhong Yu; Jinglin Yi; Xiaolong Yin; Yan Deng; Yujun Liao; Xiaobing Li
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Retinopathy of Prematurity in Neonates and its Risk Factors: A Seven Year Study in Northern Iran.

Authors:  Seyed Ahmad Rasoulinejad; Mohammad Montazeri
Journal:  Open Ophthalmol J       Date:  2016-02-29

4.  Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.

Authors:  Jeffrey J Tan; Charles L Cai; Eric M Shrier; Lois McNally; Douglas R Lazzaro; Jacob V Aranda; Kay D Beharry
Journal:  J Ophthalmol       Date:  2017-07-09       Impact factor: 1.909

5.  Abnormal Complement Activation and Inflammation in the Pathogenesis of Retinopathy of Prematurity.

Authors:  Sonika Rathi; Subhadra Jalali; Satish Patnaik; Shahna Shahulhameed; Ganeswara R Musada; Divya Balakrishnan; Padmaja K Rani; Ramesh Kekunnaya; Preeti Patil Chhablani; Sarpras Swain; Lopamudra Giri; Subhabrata Chakrabarti; Inderjeet Kaur
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

6.  Assessment of WINROP algorithm as screening tool for preterm infants in Manitoba to detect retinopathy of prematurity.

Authors:  Ebtihal Ali; Nasser Al-Shafouri; Abrar Hussain; R John Baier
Journal:  Paediatr Child Health       Date:  2017-05-08       Impact factor: 2.253

7.  CCN1/Cyr61-PI3K/AKT signaling promotes retinal neovascularization in oxygen-induced retinopathy.

Authors:  Yu Di; Yiou Zhang; Qingzhu Nie; Xiaolong Chen
Journal:  Int J Mol Med       Date:  2015-10-12       Impact factor: 4.101

Review 8.  Ischemic Retinopathies: Oxidative Stress and Inflammation.

Authors:  José Carlos Rivera; Rabah Dabouz; Baraa Noueihed; Samy Omri; Houda Tahiri; Sylvain Chemtob
Journal:  Oxid Med Cell Longev       Date:  2017-12-19       Impact factor: 6.543

9.  Retinopathy of prematurity: A comprehensive risk analysis for prevention and prediction of disease.

Authors:  Leah A Owen; Margaux A Morrison; Robert O Hoffman; Bradley A Yoder; Margaret M DeAngelis
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

Review 10.  Prevalence and risk factors of retinopathy of prematurity in Iran: a systematic review and meta-analysis.

Authors:  Milad Azami; Zahra Jaafari; Shoboo Rahmati; Afsar Dastjani Farahani; Gholamreza Badfar
Journal:  BMC Ophthalmol       Date:  2018-04-02       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.